Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: When, where and how?

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 12, 2011, Pages 1567-1571

  Trébucq, Arnaud ^a   Enarson, D A ^a   Chiang, C Y ^a   Van Deun, A ^a   Harries, A D ^a   Boillot, F ^a   Detjen, A ^a   Fujiwara, P I ^a   Graham, S M ^a   Monedero, I ^a   Rusen, I D ^a   Rieder, H L ^a  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

Diagnostics; GeneXpert; Low income countries; Tuberculosis; Xpert MTB RIF

Indexed keywords

ISONIAZID; RIFAMPICIN;

ALGORITHM; ANTIBIOTIC RESISTANCE; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; FUNDING; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE QUALITY; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOWEST INCOME GROUP; MICROSCOPY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SPUTUM SMEAR; SUSTAINABLE DEVELOPMENT; TUBERCULOSIS; TUBERCULOSIS CONTROL; XPERT MTB RIF TEST;

ALGORITHMS; ANTITUBERCULAR AGENTS; DEVELOPING COUNTRIES; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NATIONAL HEALTH PROGRAMS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RIFAMPIN; SPUTUM; TUBERCULOSIS;

EID: 81455138225     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0392     Document Type: Article

References (26)

1. Small P M, Pai M. Tuberculosis diagnosis - time for a game change. N Engl J Med 2010; 363: 1070-1071.
2. World Health Organization. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. WHO/HTM/TB/2011.4. Geneva, Switzerland: WHO, 2011.
3. World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test. Technical and operational 'How-to'. Practical considerations. WHO/HTM/TB/2011.2. Geneva, Switzerland: WHO, 2011.
4. Van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W. Xpert®MTB/RIF for point-of-care diagnosis of TB in high-HIV b urden, resource-limited countries: hype or hope? Expert Rev Mol Diagn 2010; 10: 937-946.
5. Banada P P, Sivasubramani S K, Blakemore R, et al. Containment of bioaersol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings. J Clin Microbiol 2010; 48: 3551-3557.
6. Boehme C C, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015.
7. Boehme C C, Nicol M P, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377: 1495-1504.
8. Marlowe E M, Novak Weekley S M, Cumpio J, et al. Evaluation of the Cepheid Xpert MTB/RIF assay for the direct detection of Mycobacterium tuberculosis complex from respiratory specimens. J Clin Microbiol 2011; 49: 1621-1623.
9. Moure R, Munoz L, Torres M, Santin M, Martin R, Alcaide F. Rapid detection of Mycobacterium tuberculosis complex and rifampin resistance in smear-negative clinical samples by use of an integrated real-time PCR method. J Clin Microbiol 2011; 49: 1137-1139.
10. World Health Organization. Automated real-time nucleic acid amplification technology for simultaneous and rapid detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Policy statement. WHO/HTM/TB/2011.4. Geneva, Switzerland: WHO, 2011.
11. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO progress report 2011. WHO/HTM/TB/2011.3. Geneva, Switzerland: WHO, 2011.
12. Nicol M P, Workman L, Isaacs W, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis 2011; Jul 15 [epub ahead of print].
13. Mann G, Squire S B, Bissell K, et al. Beyond accuracy: creating a comprehensive evidence base for tuberculosis diagnostic tools. Int J Tuberc Lung Dis 2010; 14: 1518-1524.
14. The Global Fund to Fight AIDS, Tuberculosis and Malaria. Scaling-up effective management of drug-resistant tuberculosis: information note. Geneva, Switzerland: Global Fund, 2011. http://www.theglobalfund.org/documents/board/22/ BM22-13TRPRound10-Report-en.pdf Accessed September 2011.
15. Van Deun A, Maug A K J, Hamid Salim M A, et al. Short, highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
16. Suchindran S, Brouwer E S, Van Rie A. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS ONE 2009; 4: e5561.
17. Gandhi N, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580. (Pubitemid 44780738)
18. Grzybowski S, Enarson D. The fate of cases of pulmonary tuberculosis under various treatment programs. Bull Int Union Tuberc 1978; 53(2): 70-75. (Pubitemid 9240283)
19. World Health Organization. WHO tuberculosis programme: framework for effective tuberculosis control. WHO/TB/94.179. Geneva, Switzerland: WHO, 1994.
20. World Health Organization. Guidance on ethics of tuberculosis prevention, care and control. WHO/HTM/TB/2010.16. Geneva, Switzerland: WHO, 2010.
21. Ma Z, Lienhardt C, McIlleron H, Nunn A J, Wang X. Global tuberculosis drug development pipeline: the need and reality. Lancet 2010; 375: 2100-2109.
22. Blower S, Supervie V. Predicting the future of XDR tuberculosis. Lancet Infect Dis 2007; 7: 743.
23. Van Rie A, Enarson D. XDR tuberculosis: an indicator of public-health negligence. Lancet 2006; 368: 1554-1556. (Pubitemid 44691898)
24. World Health Organization. Checklist of prerequisites to country implementation of Xpert MTB/RIF and key action points at country level. WHO/HTM/TB/2011.12. Geneva, Switzerland: WHO, 2011.
25. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
26. Rusen I D, Aït-Khaled N, Alarcón E, et al. Cochrane systematic review of directly observed therapy for treating tuberculosis: good analysis of the wrong outcome. Int J Tuberc Lung Dis 2007; 2: 120-121. (Pubitemid 46219272)